Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Using proteomics and transcriptomics to explore the potential gene regulatory network of immune checkpoint inhibitors-related myocarditis

ABSTRACT: Immune checkpoint inhibitor-related myocarditis is the deadliest complication of immunotherapy. However, the underlying pathophysiological mechanisms of its occurrence and development remain unclear. Due to the long-term lack of effective early diagnosis and treatment options, it is of great significance to understand the pathophysiological mechanism of immune checkpoint inhibitor-related myocarditis.

ORGANISM(S): Homo Sapiens

SUBMITTER: Jianyong Zou

PROVIDER: PXD039793 | iProX | Thu Feb 02 00:00:00 GMT 2023

REPOSITORIES: iProX

ACCESS DATA

Json Xml

Publications

Role of mitochondrial metabolism in immune checkpoint inhibitors-related myocarditis.

Zhang Xin X Gan Yi Y Zhu Haoshuai H Liu Zhihao Z Yao Xiaojing X Cheng Chao C Liu Zhenguo Z Su Chunhua C Zou Jianyong J

Frontiers in cardiovascular medicine 20230124

<h4>Background</h4>Immune checkpoint inhibitor-related myocarditis is the deadliest complication of immunotherapy. However, the underlying pathophysiological mechanisms of its occurrence and development remain unclear. Due to the long-term lack of effective early diagnosis and treatment options, it is of great significance to understand the pathophysiological mechanism of immune checkpoint inhibitor-related myocarditis.<h4>Methods</h4>Tissue samples from three patients with immune checkpoint inh ...[more]

PMID: 36760573

Similar Datasets

Comparative cardiac transcriptomics of immune checkpoint inhibitor induced myocarditis

Project description:Comparative cardiac transcriptomics of immune checkpoint inhibitor induced myocarditis

| PRJEB37155 | ENA

Immune Checkpoint Associated Acute Interstitial Nephritis

Project description:Tertiary lymphoid structure signatures are associated with immune checkpoint inhibitor related acute interstitial nephritis

| EGAD00010002406 | EGA

Comparative cardiac transcriptomics of immune checkpoint inhibitor induced myocarditis

Project description:Immune checkpoint inhibitors (ICIs) are improving cancer treatments strikingly. The raising use leads to the augmented occurrence of immune related events. Myocarditis is a rare, but severe form of these adverse events. Nine patients with proven ICI induced myocarditis were subjected to myocardial biopsy. The tissue was used for RNA-seq analyses.

2020-11-01 | E-MTAB-8867 | biostudies-arrayexpress

Stereotactic body radiation therapy (SBRT) combined with PD1 inhibitor for the treatment of colorectal cancer liver metastasis: a prospective, multicenter, phase II clinical study

Project description:Interventions: SBRT combined with placebo treatment group:SBRT combined with placebo treatment;SBRT combined with immune checkpoint inhibitor treatment group:SBRT combined with immune checkpoint inhibitor treatment Primary outcome(s): Local control and survival rates Study Design: Parallel

| 113557 | ecrin-mdr-crc

FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors

Project description:FT500 is an off-the-shelf, iPSC-derived NK cell product that can bridge innate and adaptive immunity, and has the potential to overcome multiple mechanisms of immune checkpoint inhibitor (ICI) resistance. The preclinical data provide compelling evidence supporting the clinical investigation of FT500 as monotherapy and in combination with ICI in participants with advanced solid tumors.

| 2297199 | ecrin-mdr-crc

Association of tumor burden with the efficacy of PD-(L)1 inhibitors for treatment-naive advanced non-small-cell lung cancer

Project description:A high tumor mutation was associated with a poor outcome of immune checkpoint inhibitor therapy for advanced NSCLC as a result of immunosuppressive phenotypes.

2023-12-18 | GSE250262 | GEO

QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors

Project description:This is a Phase IIb, multicohort, open-label multicenter study of combination immunotherapies in patients who have previously received treatment with PD-1/PD-L1 immune checkpoint inhibitors. All patients in Cohorts 1-4 will receive the combination treatment of PD-1/PD-L1 checkpoint inhibitor plus N-803 for up to 17 cycles. Each cycle is six weeks in duration. Some patients who experience disease progression while on study in Cohorts 1-4 may roll over into Cohort 5 and receive combination therapy with a PD-1/PD-L1 checkpoint inhibitor, N-803, and PD-L1 t-haNK cellular therapy for up to an additional 17 cycles. Each cycle is six weeks in duration. All patients will receive N-803 once every 3 weeks. Patients will also receive the same checkpoint inhibitor that they received during their previous therapy. Radiologic evaluation will occur at the end of each treatment cycle. Treatment will continue for up to 2 years, or until the patient experiences confirmed progressive disease or unacceptable toxicity, withdraws consent, or if the Investigator feels it is no longer in the patient’s best interest to continue treatment. Patients will be followed for disease progression, post-therapies, and survival through 24 months past administration of the first dose of study drug.

| 2250175 | ecrin-mdr-crc

Nitrification inhibitors in tropical soils

Project description:Nitrous oxide emission related to ammonia-oxidizing bacteria and mitigation options from N fertilization in a tropical soil

| PRJEB13027 | ENA

Gene expression profiles of melanoma tumor samples from patients treated with checkpoint inhibitors (mouse)

Project description:Checkpoint inhibitors have improved outcomes for patients with metastatic melanoma, but primary or acquired resistance often occurs. We used the mouse melanoma cell line B16, originally derived from C57BL6 mice, to model changes in tumor cell gene expression that occur with acquired resistance to checkpoint inhibitors. B16 cells used were engineered to express the fluorescent marker tdTomato, to assist monitoring and cell sorting. Previously-untreated B16 cells (F0) were inoculated into C57BL6 mice, followed by treatment with triple-checkpoint inhibitor therapy (3I) with combined antibodies to CTLA4, PD-1, and PD-L1. Tumors that emerged despite immune selection pressure were harvested, grown again in vitro as a cell line, and then re-inoculated into a new generation of mice. This was repeated for 4 generations (F4) until inoculations were 100% successful at generating immune-resistant tumors.

2020-11-01 | GSE122221 | GEO

DNA Methylation Inhibitors in Immunotherapy

Project description:<p>We show that DNA methyltransferase inhibitors (DNMTis) upregulate immune signaling in cancer through the viral defense pathway and re-expression of epigenetically silenced endogenous retrovirus. In melanoma patients treated with an immune checkpoint therapy, high viral defense signature expression in tumors significantly associates with durable clinical response and DNMTi treatment sensitizes to anti-CTLA4 therapy in a pre-clinical melanoma model.</p>

| phs001038 | dbGaP

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data